Wegovy side effects: what trials show and how to manage them

What are the most common Wegovy side effects?

Digestive effects lead by a wide margin. In STEP 1, the 68-week trial behind Wegovy's weight-management registration, 44% of participants reported nausea, 32% diarrhoea, 25% vomiting and 23% constipation. Roughly three quarters had some stomach-related symptom, yet only 4.5% stopped treatment because of one.

A tolerability analysis of the same trial softens those numbers further: 98% of the digestive complaints were mild to moderate, and they concentrated in the weeks after each dose increase. The placebo column matters too, because plenty of everyday stomach trouble gets blamed on the pen that would have happened anyway.

Beyond the big four, the label lists burping, reflux, bloating, headache, tiredness, dizziness and occasional redness or itching at the injection site as common. Most of these pass without any treatment.

Why does Wegovy cause nausea?

Because slowing digestion is part of how it works. Semaglutide activates GLP-1 receptors in the gut and brain: the stomach empties more slowly, fullness arrives earlier and appetite signalling quietens. Nausea, bloating and reflux are that mechanism overshooting while the body adapts, not a sign the medicine is causing harm.

This is why symptoms track the dose so closely. Each step up asks the digestive system to adjust again, which is when complaints flare, then fade. It is also why meals matter: a large, fatty plate on a stomach that empties slowly is the most reliable way to feel awful on this medicine.

The mechanism, and what it does to appetite and blood sugar, is unpacked in what semaglutide is and how it works.

When do Wegovy side effects start and how long do they last?

Symptoms usually start in the first weeks on a new dose and fade within days. In the STEP 1 tolerability data, the median bout of nausea lasted 8 days, diarrhoea 3 days and vomiting 2 days, almost all around dose-escalation points. Constipation is the slow one and can take weeks to settle.

Each step up the dose ladder can restart a milder version of the same cycle, so the first month on any new strength is the stretch to watch. By the time most people reach the 2.4 mg maintenance dose, the gut has had four months of gradual practice. In the tolerability analysis, reported nausea peaked around the end of the escalation phase and declined through the rest of the trial.

A symptom that persists for weeks without easing, or that returns and worsens after settling, breaks the expected pattern. That is a reason to contact your doctor rather than wait for the next review.

How does the Wegovy dose schedule limit side effects?

By starting low and climbing slowly. Wegovy begins at 0.25 mg weekly, a fraction of the full dose, and steps up roughly every four weeks until it reaches the 2.4 mg maintenance level at about week 17. Each pause gives the gut time to adapt before the next increase asks more of it.

The schedule is a starting map, not a deadline. Doctors routinely hold a dose for extra weeks when a step up bites, or drop back a level until things settle. There is no prize for reaching the top dose.

The full five-strength schedule, and what SAHPRA registered each strength for, is set out in is Wegovy available in South Africa.

How do you manage Wegovy side effects at home?

Mostly with food and fluid tactics. Smaller meals eaten slowly, stopping at the first signal of fullness, and lower-fat food during dose-increase weeks handle most nausea. Constipation responds to water first, then fibre, then movement. On diarrhoea days, rehydrate with an oral rehydration solution from any pharmacy.

Burping and reflux have their own fixes: smaller evening meals, finishing food two to three hours before bed, and staying upright for a while after eating. A pharmacist can suggest an antacid if reflux keeps bothering you between doctor reviews.

Timing helps too. Inject on the same day each week and pick a day where a rough 24 hours costs least, since symptoms often peak the day after a dose. Rotating the site between stomach, thigh and upper arm limits skin irritation.

What you eat shapes most of this, and a practical plan is in what to eat on GLP-1 medication. The class-wide playbook, remedy by remedy, is in managing GLP-1 side effects. If home measures are not holding a symptom down, message your doctor; a longer hold at the current dose usually fixes what willpower cannot.

Which Wegovy side effects are serious?

A short list, and each is rare. Acute pancreatitis, gallbladder disease, severe dehydration, serious allergic reactions and a rare eye condition are the ones regulators highlight. The headline symptom is severe, persistent stomach pain, sometimes radiating to the back: stop injecting and seek medical care immediately.

The UK regulator strengthened the pancreatitis warning for all GLP-1 medicines in January 2026 after rare reports of necrotising and fatal cases. Scale keeps that in proportion: about 1,300 UK pancreatitis reports across the class since 2007, set against an estimated 25 million packs dispensed in the past five years.

Gallstone problems affected 2.6% of STEP 1 participants against 1.2% on placebo, partly because rapid weight loss from any cause raises the risk. Semaglutide also caused thyroid C-cell tumours in rodent studies; whether that translates to humans is unknown, and a new lump in the neck, hoarseness or trouble swallowing should be examined promptly.

Can Wegovy affect your eyes?

Rarely, and the warning is recent. NAION, a sudden and painless loss of vision usually in one eye, may affect up to 1 in 10,000 people using semaglutide, and the UK regulator MHRA formalised the warning in February 2026. Sudden vision loss, even partial, means seek medical care immediately.

If an eye specialist confirms NAION, semaglutide is stopped. The absolute numbers stay very small, which is why the advice is urgent referral when vision changes rather than routine eye testing for everyone.

Separately, people with type 2 diabetes who already have diabetic retinopathy need eye monitoring during treatment, because rapidly improving blood sugar can temporarily worsen that condition. This warning sits on the label and belongs in the assessment conversation from the start.

Who should not use Wegovy?

Some exclusions are firm. Wegovy is not used during pregnancy, while trying to conceive or while breastfeeding, and not by anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome. A previous serious allergic reaction to semaglutide also rules it out. The South African registration covers adults and, under strict criteria, adolescents from age 12; younger children are excluded.

Other histories call for judgement rather than automatic exclusion: past pancreatitis, severe gut disease such as gastroparesis, and type 1 diabetes, where this medicine is no substitute for insulin. Combining it with insulin or a sulfonylurea changes the low blood sugar risk entirely, so every medicine you take belongs in the conversation.

Two disclosures matter beyond the checklist. Tell any surgical or anaesthetic team that you use semaglutide, because a stomach that empties slowly matters when you must fast before an operation. And mention tablets whose timing is sensitive, since slower digestion can shift how they are absorbed. All of this is what the initial doctor assessment screens for, and what to expect from your first consultation sets it out step by step.

What about hair loss, tiredness and other effects?

They are real, and mostly mild. In the trial data on the South African label, 2.5% of adults on Wegovy reported hair loss against 1% on placebo, linked mainly to rapid weight loss itself rather than the molecule. Fatigue, headache and dizziness appear on the label as common, and average heart rate rose by about 3 beats per minute.

Shed hair usually regrows once weight stabilises, and tiredness tends to ease as eating patterns find a new level. Dizziness often traces back to eating or drinking too little on a suppressed appetite, so small regular meals and steady fluids solve most of it. A racing or pounding heart that persists is different: raise it with your doctor.

Rapid weight loss can also change the face and body in ways people notice before the scale does, from hollowed cheeks to looser skin. These are effects of losing weight quickly by any method, and slowing the rate of loss is often the fix.

Do side effects mean Wegovy is working?

No. In the STEP 1 tolerability analysis, people who had no digestive side effects lost almost the same weight as people who did, so nausea is not a progress report. Judging the dose by discomfort points the wrong way in both directions.

Feeling fine does not mean the dose is too low, and feeling rough does not mean the medicine has finally kicked in. Progress is measured by the scale, the tape measure and your doctor's reviews.

The benefit side of the ledger holds regardless of symptoms. STEP 1 recorded 14.9% average weight loss over 68 weeks, and 86% of participants lost at least 5% of body weight. Individual results vary.

How do Wegovy side effects compare with Ozempic and Mounjaro?

Closely, because the medicines share a mechanism. Ozempic contains the same molecule, semaglutide, at lower maximum doses, and is registered for type 2 diabetes rather than weight management, so its digestive profile is the same shape. Mounjaro, which contains tirzepatide, reports the same cluster at broadly similar rates.

Tirzepatide's SURMOUNT trials report nausea somewhat less often than STEP 1's 44%, though different trials measure differently and head-to-head tolerability data is thin. The trial numbers for that medicine are in Mounjaro side effects, and the dose-by-dose detail for the diabetes pen is in Ozempic side effects.

None of this ranks the medicines. Side-effect profiles are one input beside trial results, availability and your medical history, and the right option is decided by a doctor on assessment.

How are side effects handled in South African care?

Through scheduled follow-up. Wegovy is a Schedule 4 medicine, registered by SAHPRA for chronic weight management and on sale in South Africa since August 2025, so treatment runs under a doctor's assessment and authorisation. A review before each dose change is where most side effects surface and get solved.

South Africans can report suspected side effects directly to SAHPRA through its Med Safety app or reporting forms, alongside telling their doctor and pharmacist. Those reports feed the safety monitoring that keeps the local label current.

One caution completes the picture. SAHPRA has warned repeatedly about falsified and compounded "semaglutide" sold on social media and unverified websites; those products have no quality control, and their side effects are anyone's guess. The registered pen, dispensed by a licensed pharmacy after a doctor confirms a treatment plan, is the only version whose contents have been checked.

Frequently asked questions